Integra LifeSciences EVP granted 11,180 RSUs

DAVIS ROBERT T. JR. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

DAVIS ROBERT T. JR. reported acquisition or exercise transactions in this Form 4 filing.

Integra LifeSciences Holdings Corp executive Robert T. Davis Jr., EVP & President, TR&DT, received a grant of 11,180 restricted stock units (RSUs) tied to the company’s common stock. These RSUs were awarded under the company’s Fifth Amended and Restated 2003 Equity Incentive Plan as part of equity compensation.

Each RSU represents a contingent right to receive one share of common stock and will vest in full on the second anniversary of the grant date, assuming he continues in service through that date. Following this award, Davis directly holds 54,530 RSUs in total.

Insider Trade Summary

Grant/Award: 11,180 shares

Grant/Award 1 txn

Insider DAVIS ROBERT T. JR.

Role EVP & President, TR&DT

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	11,180	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 54,530 contracts (Direct)

Footnotes (2)

1. F1. Grant of restricted stock units ("RSUs") pursuant to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
2. F2. All RSUs reported in this row were granted under the Plan and will vest in full on the second anniversary of the grant date, subject to the Reporting Person's continued service through such date.

Key Figures

RSUs granted: 11,180 units Grant price per RSU: $0.00 per unit Total RSUs after grant: 54,530 units +1 more

4 metrics

RSUs granted 11,180 units Grant of restricted stock units to EVP on July 1, 2026

Grant price per RSU $0.00 per unit Compensation award, not an open-market purchase

Total RSUs after grant 54,530 units Direct holdings of restricted stock units following the transaction

Vesting schedule 2 years from grant date RSUs vest in full on second anniversary, subject to continued service

Key Terms

Restricted Stock Units, Equity Incentive Plan, contingent right, vest in full

4 terms

Restricted Stock Units financial

"Grant of restricted stock units ("RSUs") pursuant to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Equity Incentive Plan financial

"pursuant to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan")"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's common stock."

vest in full financial

"will vest in full on the second anniversary of the grant date, subject to the Reporting Person's continued service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Integra LifeSciences (IART) report for Robert T. Davis Jr.?

Integra LifeSciences reported that EVP & President, TR&DT Robert T. Davis Jr. received a grant of 11,180 restricted stock units. These units are part of his equity compensation and are tied to future delivery of common stock upon vesting.

How many restricted stock units did the IART executive receive in this Form 4 filing?

The executive was granted 11,180 restricted stock units. Each RSU represents a right to receive one share of Integra LifeSciences common stock in the future, subject to vesting conditions outlined in the company’s equity incentive plan.

When do the newly granted Integra LifeSciences (IART) RSUs vest?

All the reported RSUs will vest in full on the second anniversary of the grant date. Vesting is contingent on Robert T. Davis Jr.’s continued service with Integra LifeSciences through that two-year period under the equity incentive plan.

What is the cost per share for the RSUs granted to the IART executive?

The RSUs were granted at a price of $0.00 per unit, reflecting a compensation award rather than a market purchase. Value to the executive depends on Integra LifeSciences’ common stock price when the RSUs ultimately vest and settle.

How many Integra LifeSciences RSUs does Robert T. Davis Jr. hold after this grant?

After this grant, Robert T. Davis Jr. directly holds 54,530 restricted stock units. This total includes the newly awarded 11,180 RSUs, all of which relate to future delivery of Integra LifeSciences common stock upon vesting and settlement.

Under what plan were the new IART restricted stock units granted?

The RSUs were granted under Integra LifeSciences Holdings Corporation’s Fifth Amended and Restated 2003 Equity Incentive Plan, as amended. This plan governs the terms, vesting conditions, and settlement of equity awards such as restricted stock units to company executives.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 04:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DAVIS ROBERT T. JR.

(Last) (First) (Middle)

1100 CAMPUS ROAD

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & President, TR&DT

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	07/01/2026		A		11,180		(2)	(2)	Common Stock	11,180	$0	54,530	D

Explanation of Responses:

1. Grant of restricted stock units ("RSUs") pursuant to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

2. All RSUs reported in this row were granted under the Plan and will vest in full on the second anniversary of the grant date, subject to the Reporting Person's continued service through such date.

Remarks:

	/s/ Lesha Shinn; Attorney-in-Fact for Robert T. Davis	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)